Serotonin syndrome masquerading as disease flare in lupus nephritis with end-stage renal disease

被引:6
|
作者
Navarroza, Rodeo, V [1 ]
Zamora, Leonid D. [1 ]
Navarra, Sandra, V [1 ]
机构
[1] Univ Santo Tomas Hosp, Sect Rheumatol, Manila, Philippines
关键词
end-stage renal disease; linezolid; lupus nephritis; serotonin syndrome; serotonin toxicity; TRAMADOL; TOXICITY;
D O I
10.1111/1756-185X.13683
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Serotonin syndrome is a potentially life-threatening condition characterized by the triad of mental status changes, autonomic instability, and neuromuscular changes. We report a case of serotonin syndrome masquerading as disease flare in a lupus nephritis patient with end-stage renal disease receiving linezolid for the treatment of infected pseudoaneurysm. Case report A 36-year-old female lupus nephritis patient on maintenance hemodialysis for end-stage renal disease had been on multiple antibiotics, including anti-tuberculosis medications, over the past month for infected pseudoaneurysm complicating her arteriovenous fistula. Due to minimal response, she underwent pseudoaneurysmal ligation and given linezolid. Two days later, she developed chest pain, tachycardia, hypertension, tremors, later accompanied by high-grade fever, diarrhea, insomnia, and body weakness. Although fully awake and oriented, she was markedly agitated, mildly icteric, had hyperreflexia and asthenia with proximal muscle strength graded 3/5 in all extremities. Blood counts revealed anemia and thrombocytopenia; ancillary tests showed aspartate aminotransferase markedly higher than alanine aminotransferase, elevated serum lactate dehydrogenase and creatine kinase, and low C3 levels. Intravenous hydrocortisone was started for a suspected lupus flare. On the background of linezolid, isoniazid, and tramadol administration, serotonin syndrome with rhabdomyolysis was strongly considered. Offending drugs were discontinued, resulting in the dramatic improvement of symptoms and improved strength and well-being. The steroid was successfully tapered to 5 mg/day and a week later, she remained afebrile without recurrence of symptoms. Conclusion Serotonin syndrome should be considered in patients on multiple serotonergic agents on the background of end-stage renal disease. Prompt recognition and distinction from lupus activity can significantly impact management decisions.
引用
收藏
页码:1933 / 1936
页数:4
相关论文
共 50 条
  • [31] Incidence of end-stage renal disease due to lupus nephritis in the US,1995-2004
    Costenbader, Karen H.
    Solomon, Daniel H.
    Winkelmayer, Wolfgang
    Brookhart, M. Alan
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S873 - S873
  • [32] Post-transplant Outcomes of Patients with End-Stage Renal Disease Caused by Lupus Nephritis
    Eigbire-molen, Odianosen
    Napier, Johnathan
    Coley, Shana
    Caza, Tiffany
    [J]. LABORATORY INVESTIGATION, 2023, 103 (03) : S1435 - S1436
  • [33] Predictors of end-stage renal disease and recurrence of lupus activity after initiation of dialysis in patients with lupus nephritis
    Moon, S. -J.
    Park, H. S.
    Kwok, S. -K.
    Ju, J. H.
    Kim, H. -Y.
    Park, S. -H.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (01) : 31 - 39
  • [34] PREDICTORS OF END-STAGE RENAL DISEASE AND RECURRENCE OF LUPUS ACTIVITY AFTER INITIATION OF DIALYSIS IN PATIENTS WITH LUPUS NEPHRITIS
    Moon, S. -J.
    Kwok, S. -K.
    Ju, J. H.
    Min, J. -K.
    Kim, H. -Y.
    Park, S. -H.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 552 - 553
  • [35] Sustained complete renal remission is a predictor of reduced mortality, chronic kidney disease and end-stage renal disease in lupus nephritis
    Pakchotanon, R.
    Gladman, D. D.
    Su, J.
    Urowitz, M. B.
    [J]. LUPUS, 2018, 27 (03) : 468 - 474
  • [36] Time to renal disease and end-stage renal disease in PROFILE:: A multiethnic lupus cohort
    Alarcon, Graciela S.
    McGwin, Gerald, Jr.
    Petri, Michelle
    Ramsey-Goldman, Rosalind
    Fessler, Barri J.
    Vila, Luis M.
    Edberg, Jeffrey C.
    Reveille, John D.
    Kimberly, Robert P.
    [J]. PLOS MEDICINE, 2006, 3 (10) : 1949 - 1956
  • [37] PREDICTORS OF END STAGE RENAL DISEASE IN THE RENAL BIOPSY PROVEN LUPUS NEPHRITIS
    Duran, E.
    Yildirim, T.
    Kalyoncu, U.
    Taghiyeva, A.
    Saglam, E. Arzu
    Uner, M.
    Bilgin, E.
    Jabrayilov, J.
    Bolek, E. C.
    Onal, C.
    Farisogullari, B.
    Koc, N. S.
    Yardimci, G. K.
    Girgin, S.
    Ayan, G.
    Ozsoy, Z.
    Uzun, G. Sandal
    Kilic, L.
    Yilmaz, S. R.
    Akdogan, A.
    Bilgen, S. A.
    Karadag, O.
    Kiraz, S.
    Altun, B.
    Ertenli, A. I.
    Arici, M.
    Erdem, Y.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 648 - 649
  • [38] Improving Outcomes in Patients with Lupus and End-Stage Renal Disease
    Inda-Filho, Antonio
    Neugarten, Joel
    Putterman, Chaim
    Broder, Anna
    [J]. SEMINARS IN DIALYSIS, 2013, 26 (05) : 590 - 596
  • [39] Cardiovascular and cerebrovascular morbidity and mortality among women with end-stage renal disease attributable to lupus nephritis
    Ward, MM
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 36 (03) : 516 - 525
  • [40] LUPUS NEPHRITIS IN MALES : PROGNOSTIC FACTORS FOR END STAGE RENAL DISEASE
    Melek, Kharroubi
    Raja, Aouidia
    Hanene, Gaid
    Mouna, Jerbi
    Soumaya, Chargui
    Hayet, Kaaroud
    Hedri, Hafedh
    Mondher, Ounissi
    Fethi, Ben Hmida
    Rim, Goucha
    Taib, Ben Abdallah
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33